title: An update on RAAS blockade and peritoneal membrane preservation: the ace of art.
abstract: Peritoneal membrane changes over time in long-term peritoneal dialysis (PD) patients lead to dialysis failure and increased morbidity as well as mortality. Bio-incompatable PD solution, peritonitis, and uremia are hypothesized in causing membrane damage. Fibrous organization and angiogenesis of peritoneum are crucial morphological alterations which can diminish the efficacy of exchange and cause ultrafiltration failure. Pathophysiologic mechanisms of membrane damage have been extensively studied to innovate therapeutic strategies. One of the potential mechanisms is a presence of local renin-angiotensin-aldosterone system (RAAS) by which injured peritoneal mesothelial cell-derived angiotensin-II (AII) causes activations in TGF-beta, VEGF expression, and epithelial-to-mesenchymal transition (EMT) which contributes to extracellular matrix accumulation and neoangiogenesis in submesothelial tissues. Clinical evidence of RAAS blockade on human peritoneal membrane remains under investigation and is still inconclusive but relevant data seem to demonstrate its benefit on membrane preservation. Longitudinal effect of RAAS blockade on membrane structural, functional, and clinical relationships and strategies to use angiotensin converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), aldosterone antagonist, and direct renin inhibitor are an interesting field to be explored.
authors: Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. wassa_jo@hotmail.com
authors: Wassawon
authors: W
authors: Wontanatawatot
authors: Somchai
authors: S
authors: Eiam-Ong
authors: Asada
authors: A
authors: Leelahavanichkul
authors: Talerngsak
authors: T
authors: Kanjanabuch
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D004847:Epithelial Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000494:pharmacology; D010530:Peritoneal Dialysis; D010537:Peritoneum / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D012083:Renin / Q000494:pharmacology; D012084:Renin-Angiotensin System; D016212:Transforming Growth Factor beta / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D016212:Transforming Growth Factor beta; D042461:Vascular Endothelial Growth Factor A; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D012083:Renin